Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: A retrospective cohort study

Oncotarget

Volumn 7, Issue 26, 2016, Pages 40085-40094

  Verzoni, Elena ^a   de Giorgi, Ugo ^b   Derosa, Lisa ^c   Caffo, Orazio ^d   Boccardo, Francesco ^e   Facchini, Gaetano ^f   Porcu, Luca ^g   de Vincenzo, Fabio ^h   Zaniboni, Alberto ⁱ   Chiuri, Vincenzo Emanuele ^j   Fratino, Lucia ^k   Santini, Daniele ^l   Adamo, Vincenzo ^m   de Vivo, Rocco ⁿ   Dinota, Angelo ^o   Messina, Caterina ^p   Ricotta, Riccardo ^q   Caserta, Claudia ^r   Scavelli, Claudio ^s   Susi, Marina ^t   Tartarone, Alfredo ^u   Surace, Giuseppe ^v   Mosca, Alessandra ^w   Bruno, Michele ^x   Barni, Sandro ^y   Grassi, Paolo ^a   Procopio, Giuseppe ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c ISTITUTO TOSCANO TUMORI   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

ⁱ Fondazione Poliambulanza   (Italy)

^j VITO FAZZI HOSPITAL   (Italy)

^k CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^l UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^m Operative Unit of Medical Oncology   (Italy)

ⁿ SAN BORTOLO HOSPITAL   (Italy)

^o SAN CARLO HOSPITAL   (Italy)

^p Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^q OSPEDALE NIGUARDA CA GRANDA   (Italy)

^r Santa Maria University Hospital   (Italy)

^s Oncology Unit   (Italy)

^t Ospedale Madonna Delle Grazie   (Italy)

^u REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^v Ospedale D Camberlingo   (Italy)

^w MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^x ASL Taranto   (Italy)

^y AO   (Italy)

more..

Author keywords

Abiraterone acetate; Castration resistant; Predictive factors; Prostate cancer; Retrospective studies

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; DOCETAXEL; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE METASTASIS; CANCER CONTROL; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL FEATURE; COHORT ANALYSIS; DIARRHEA; DRUG EXPOSURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GLEASON SCORE; HUMAN; HYPOKALEMIA; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VISCERAL METASTASIS; BLOOD; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; FOLLOW-UP STUDIES; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84982980466     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9485     Document Type: Article

References (26)

1. Antonarakis ES. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key? Expert Rev Anticancer Ther. 2015; 15: 3-5.
2. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015; 26: 1859-65.
3. Attard G, Beltran H. Prioritizing precision medicine for prostate cancer. Ann Oncol. 2015; 26: 1041-2.
4. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015; 26: 1589-604.
5. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, et al.; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13: 983-92.
6. Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012; 61: 549-59.
7. Löffeler S, Weedon-Fekjaer H, Wang-Hansen MS, Sebakk K, Hamre H, Haug ES, Fosså SD. "Natural course" of disease in patients with metastatic castrate-resistant prostate cancer: Survival and prognostic factors without life-prolonging treatment. Scand J Urol. 2015; 1-6 [Epub ahead of print].
8. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006; 12: 3361-7.
9. Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, Tannock IF. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012; 30: 607-13.
10. van Soest RJ, de Morrée ES, Shen L, Tannock IF, Eisenberger MA, de Wit R. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. Eur Urol. 2014; 66: 330-6.
11. Höfner T, Vallet S, Hadaschik BA, Pahernik S, Duensing S, Hohenfellner M, Jäger D, Grüllich C. Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort. World J Urol. 2015; 33: 833-9.
12. Fizazi K, Flaig TW, Stockle M, Scher HI, de Bono JS, Rathkopf DE, Ryan CJ, Kheoh T, Li J, Todd MB, Griffin TW, Molina A and Ohlmann CH. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol. 2016; 27: 699-705.
13. Afshar M, Al-Alloosh F, Pirrie S, Rowan C, James ND, Porfiri E. Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer. Anticancer Res. 2015; 35: 1057-63.
14. Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. Eur J Cancer. 2015; 51: 1946-52.
15. Goodman OB Jr, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014; 17: 34-9.
16. Iuliani M, Pantano F, Buttigliero C, Fioramonti M, Bertaglia V, Vincenzi B, Zoccoli A, Ribelli G, Tucci M, Vignani F, Berruti A, Scagliotti GV, Tonini G, Santini D. Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget. 2015; 14: 12520-12528. doi: 10.18632/oncotarget.3724.
17. Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Griffin TW, Kheoh T, Ricci DS, et al. Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Clin Cancer Res. 2015; 21: 1621-7.
18. De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, Fabbri F, Carretta E, Amadori D, Paganelli G, Matteucci F. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget. 2014; 5: 12448-58. doi: 10.18632/oncotarget.2558.
19. Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono JS. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015; 26: 750-5.
20. Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, McCormack R, Burzykowski T, Kheoh T, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015; 33: 1348-55.
21. Lorente, Olmos D, Mateo J, Bianchini D, Seed G, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Pitfield T, Molina A, Kheoh T, et al. Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): analysis of the COU-AA-301 and IMMC38 trials. J Clin Oncol. 2015; 33.
22. Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, Vera-Badillo F, Seah JA, Attard G, Knox JJ, Sridhar SS, Tannock IF, de Bono JS, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014; 25: 657-62.
23. De Giorgi U, Crabb SJ, Jones RJ, Caffo O, Elliott T, Fabbri P, Derosa L, Massari F, Numico G, Conteduca V, Zarif S, Hanna C, Maines F, et al. High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol. 2015; 33.
24. Houédé N, Beuzeboc P, Gourgou S, Tosi D, Moise L, Gravis G, Delva R, Fléchon A, Latorzeff I, Ferrero JM, Oudard S, Tartas S, Laguerre B, et al. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for use programme in France. BMC Cancer. 2015, 15: 222.
25. Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade SR, Carducci MA, Eisenberger MA. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. Prostate. 2016; 76: 512-520.
26. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Wadsworth & Brooks/Cole, Pacific Grove, CA, 1984.